Overlooked Treatments

COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis | The Medical Letter Inc.

Monoclonal Antibody Authorized to Protect At-Risk People From COVID-19

Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial

Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19

Plasma taurine level is linked to symptom burden and clinical outcomes in post-COVID condition

Researchers identify amino acid that may play a key role for predicting and treating long COVID

Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study

From a Grassroots Survey to Long Covid Treatment Trials

Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations

Narrative Service

Americans Don’t Get to Have the Best New COVID Drug

Further patients benefit from drug against Long COVID

Long COVID: Study Says Synbiotic Drug That Alters Gut Microbiome Relieves Multiple Symptoms

NIH Launches Trials for Long COVID Treatment Breakthroughs

Intravenous immunoglobulin as a potential treatment for long COVID

Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection

Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review - PubMed

Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms

Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Long COVID Looks Like Acute Infection in the Brain

Frontiers | Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)

Study Details | Antiviral Clinical Trial for Long Covid-19 | ClinicalTrials.gov

(16) Post-Viral Trials News (@postviraltrials) / X

RECOVER Clinical Trials | Home

Monoclonal antibody levels and protection from COVID-19

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir

Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro

Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout | Clinical Infectious Diseases | Oxford Academic